Stockreport

Abpro and Celltrion, Inc. Announce U.S. FDA IND Clearance for Lead Multispecific Antibody Cancer Candidate ABP-102 / CT-P72 [Yahoo! Finance]

Abpro Holdings, Inc  (ABP) 
NASDAQ:AMEX Investor Relations: abpro.com/contact
PDF Clinical trial anticipated to commence in the first half of 2026 through Abpro's global collaboration with Celltrion BURLINGTON, Mass. and INCHEON, South Korea, Jan. [Read more]